Research DisclaimerFor educational purposes only. Retatrutide is supplied strictly for laboratory research use. Not medical advice. Not for human or animal consumption.

What Is Retatrutide?

Retatrutide — also referenced in pharmacological literature as LY3437943 — is a synthetic research peptide developed as a triple receptor agonist. Unlike earlier generation GLP-1 compounds that targeted a single receptor pathway, Retatrutide simultaneously activates three distinct hormone receptors: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor.

This multi-receptor approach represents one of the most significant advances in metabolic peptide research. Single-receptor GLP-1 agonists such as Semaglutide, and dual-receptor agonists such as Tirzepatide, established a clear scientific trajectory toward broader receptor engagement. Retatrutide extends this further by incorporating glucagon receptor activation — a mechanism that has attracted considerable scientific attention.

121 Peptides supplies Retatrutide as a research peptide in vial formats from 5mg to 60mg, strictly for laboratory and analytical research use only.

The Triple Receptor Mechanism: GLP-1, GIP and Glucagon

GLP-1 Receptor Agonism

The glucagon-like peptide-1 receptor is expressed predominantly in the pancreas, brain, gut, heart and kidneys. GLP-1 is an incretin hormone naturally secreted by intestinal L-cells in response to nutrient intake. Its activation promotes insulin secretion in a glucose-dependent manner, suppresses glucagon release, slows gastric emptying and generates satiety signals in the hypothalamus. The GLP-1 component of Retatrutide replicates and extends these studied effects, forming the foundation of its metabolic research profile.

GIP Receptor Agonism

Glucose-dependent insulinotropic polypeptide (GIP) is the second incretin hormone, secreted by K-cells in the small intestine. Like GLP-1, GIP stimulates insulin secretion in a glucose-dependent manner. GIP also has direct effects on adipose tissue, and research has explored its role in energy storage and expenditure regulation. Dual GLP-1/GIP agonists such as Tirzepatide demonstrated that combining these two incretin pathways produces additive — and in some research models synergistic — effects. Retatrutide builds on this by adding the third receptor arm.

Glucagon Receptor Agonism

Glucagon is traditionally a counter-regulatory hormone to insulin. At the receptor level, however, glucagon plays a significant role in energy expenditure. Research in laboratory models has shown that glucagon receptor activation increases thermogenesis, promotes fat oxidation in the liver, and can substantially increase resting metabolic rate. Incorporating glucagon receptor agonism into a GLP-1/GIP framework theoretically allows Retatrutide to address both energy intake — via appetite suppression — and energy expenditure — via metabolic rate elevation — simultaneously.

Key Research Areas

Retatrutide vs Other Research Peptides

Scientific Context and Research Significance

The progression from single to dual to triple receptor agonism in metabolic peptide research reflects a broader scientific understanding that energy homeostasis is governed by multiple interacting hormonal systems rather than a single pathway. Retatrutide's design attempts to address this complexity by engaging three complementary systems.

The GLP-1 component provides established incretin-mediated appetite regulation. The GIP component adds a parallel incretin pathway with distinct but complementary effects. The glucagon component introduces an entirely different mechanism — one focused on energy output rather than energy input — creating what researchers have described as a complementary push-pull dynamic on energy balance.

This theoretical framework has made Retatrutide one of the most actively discussed research peptides in current metabolic science, with interest spanning academic institutions, pharmaceutical research divisions and independent laboratory settings worldwide.

Research Formats Available from 121 Peptides

Frequently Asked Questions

Related Research Articles

Enquire About Retatrutide Research Supply

121 Peptides supplies Retatrutide in multiple formats for laboratory research. Submit a research enquiry to discuss availability.

Research DisclaimerFor educational purposes only. BPC 157 is supplied strictly for laboratory research use. Not medical advice. Not for human or animal consumption.

What Is BPC 157?

BPC 157 — Body Protective Compound 157 — is a synthetic pentadecapeptide consisting of 15 amino acids. It is derived from a partial sequence of a naturally occurring protein found in human gastric juice, referred to in the literature as Body Protective Compound or BPC. The specific sequence studied under the BPC 157 designation is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val.

This peptide has been the subject of extensive laboratory research since the early 1990s, originating primarily from work conducted at the University of Zagreb, where researchers isolated and synthesised peptide sequences from gastric juice and began investigating their biological properties in preclinical models.

121 Peptides supplies BPC 157 in 5mg, 10mg and 20mg vial formats for laboratory research use only.

Chemical and Structural Background

BPC 157 has the molecular formula C62H98N16O22 and a molecular weight of approximately 1419.5 Da. As a pentadecapeptide, it consists of a precisely ordered 15-amino-acid chain. Unlike many peptides studied in pharmacological research, BPC 157 demonstrates notable stability in gastric acid environments — a property linked to its origin from gastric-derived proteins and one that has shaped the design of laboratory research protocols involving the compound.

The peptide is water soluble and has been studied in both aqueous solution and lyophilised (freeze-dried) formats. Most laboratory research uses reconstituted preparations in sterile water or acetic acid solutions, which is reflected in the research supply formats offered by 121 Peptides.

Proposed Mechanisms in Research

Laboratory research into BPC 157 has proposed several mechanisms through which the peptide may exert its studied effects. These are research hypotheses derived from preclinical studies and should not be taken as established medical fact.

Areas of Laboratory Research Investigation

BPC 157 has been studied across a broad range of tissue types and biological systems in preclinical research. The main areas of scientific investigation include:

Musculoskeletal and Connective Tissue Research

A substantial body of preclinical research has investigated BPC 157 in the context of tendon, ligament and muscle tissue. Studies have used rodent models of Achilles tendon transection, medial collateral ligament injury and muscle crush injury to examine whether BPC 157 influences the rate and quality of tissue repair processes. Fibroblast behaviour, collagen organisation and tissue tensile properties have been among the outcomes studied.

Gastrointestinal Research

The gastrointestinal tract has been one of the most extensively researched tissue systems for BPC 157. Studies have examined its effects in models of gastric ulceration induced by various agents (NSAID exposure, ethanol, acetic acid), as well as models of inflammatory bowel conditions, short bowel syndrome and intestinal anastomosis. The stability of BPC 157 in gastric environments has made it a notable subject for oral route research in gastrointestinal contexts.

Bone and Joint Research

Preclinical studies have explored BPC 157 in bone fracture and joint injury models, examining markers of bone remodelling, callus formation and cartilage integrity. Research interest in joint-related applications has extended to models of osteoarthritis and surgical joint procedures.

Neurological and Brain Research

A growing area of interest involves BPC 157's effects in neurological models. Studies have examined outcomes in models of traumatic brain injury, peripheral nerve transection, dopaminergic pathway research and general neuroprotection models. These represent an emerging and less developed area of research compared to the musculoskeletal and gastrointestinal fields.

BPC 157 vs TB500: Comparing Two Recovery Research Peptides

BPC 157 and TB500 (Thymosin Beta-4) are frequently discussed together in recovery-focused peptide research. While they are studied for overlapping outcomes, their mechanisms and structural origins are distinct.

Frequently Asked Questions About BPC 157

Related Research Articles

Enquire About BPC 157 Research Supply

121 Peptides supplies BPC 157 in 5mg, 10mg and 20mg formats for laboratory research. Submit a research enquiry.

Research DisclaimerFor educational purposes only. TB500 is supplied strictly for laboratory research use. Not medical advice. Not for human or animal consumption.

What Is TB500?

TB500 is a synthetic research peptide derived from a conserved region of Thymosin Beta-4 (Tβ4) — a naturally occurring 43-amino-acid protein found ubiquitously in mammalian cells and tissues. The specific sequence studied under the TB500 designation is the actin-binding domain of Thymosin Beta-4: Ac-LKKTETQ (and its extended variants), which represents the most biologically active portion of the parent protein as identified in research settings.

Thymosin Beta-4 was originally isolated from calf thymus tissue in the 1960s, initially described as one of a family of thymic peptides with potential immunoregulatory properties. Subsequent research revealed that Tβ4 is expressed across a remarkably wide range of cell types — far beyond the thymus — and plays fundamental roles in actin dynamics, cell motility and tissue development. It is among the most abundant proteins in mammalian cells.

121 Peptides supplies TB500 in 5mg and 10mg vial formats for laboratory research use only.

The Core Mechanism: Actin Sequestration

The primary understood mechanism of Thymosin Beta-4 — and by extension TB500 — centres on its role as an actin-sequestering peptide. Actin is one of the most abundant proteins in eukaryotic cells, forming the dynamic cytoskeletal networks that govern cell shape, division, and movement.

Cellular actin exists in two forms: globular monomeric G-actin and filamentous polymeric F-actin. The balance between these forms determines cell structure and motility. Thymosin Beta-4 binds to G-actin monomers, regulating the pool of actin available for polymerisation. This sequestration role means Tβ4 is a key regulator of the actin treadmilling process — the dynamic addition and removal of actin monomers at filament ends.

In research models, this actin regulation function has been linked to cell migration behaviours, which is relevant to wound healing, tissue repair and developmental biology research. When cells need to migrate — as occurs in wound closure and tissue regeneration — the availability of G-actin monomers, regulated by Tβ4, is a limiting factor in cell locomotion.

Key Research Areas

Thymosin Beta-4 vs TB500: Understanding the Distinction

It is important to clarify the relationship between Thymosin Beta-4 (Tβ4) and the research peptide TB500, as the terms are sometimes used interchangeably in research contexts.

Full-length Thymosin Beta-4 is a 43-amino-acid peptide. TB500 is a shorter synthetic analogue — typically representing the active actin-binding domain of Tβ4 — selected for research purposes based on its stability, bioavailability in laboratory models and the concentration of studied biological activity in that specific sequence. The Ac-LKKTETQ sequence (and immediate surrounding residues) represents the core actin-sequestering region of the parent molecule.

When 121 Peptides references TB500, this refers to this synthetic research analogue derived from Thymosin Beta-4, supplied strictly for laboratory research purposes.

TB500 in the Context of Peptide Blends

TB500 is also a component in two of 121 Peptides' blended research formats — GLOW70 and KLOW80 — where it is combined with BPC 157 and GHK-CU (and in the case of KLOW80, KPV) to create multi-peptide research formulations targeting overlapping recovery and regenerative pathways.

Research interest in combining TB500 with BPC 157 specifically stems from their complementary mechanisms: BPC 157's primary research focus on the NO system and growth factor expression versus TB500's primary focus on actin dynamics and cell migration. These are viewed in the research literature as potentially synergistic rather than redundant mechanisms.

Frequently Asked Questions About TB500

Related Research Articles

Enquire About TB500 Research Supply

121 Peptides supplies TB500 in 5mg and 10mg formats for laboratory research. Submit a research enquiry.

Research DisclaimerFor educational purposes only. GHK-CU is supplied strictly for laboratory research use. Not medical advice. Not for human or animal consumption.

What Is GHK-CU?

GHK-CU — glycyl-L-histidyl-L-lysine copper — is a naturally occurring tripeptide copper complex first identified in human plasma in 1973. The peptide consists of three amino acids (glycine, histidine and lysine) bound to a copper(II) ion. This copper chelation is central to its biological properties and distinguishes it from non-copper-bound GHK peptide.

GHK-CU is found in several biological fluids and tissues including plasma, saliva and urine, with plasma concentrations showing an age-dependent decline — a fact that has made it a subject of particular interest in ageing biology research. In young adults, plasma GHK-CU concentrations are notably higher than in older individuals, a pattern researchers have studied in relation to age-related changes in tissue repair capacity and skin integrity.

121 Peptides supplies GHK-CU in 50mg and 100mg vial formats for laboratory research use only.

The Chemistry of GHK-CU: Why Copper Matters

The copper component of GHK-CU is not incidental — it is pharmacologically central. Copper is an essential trace element involved in multiple enzymatic systems including superoxide dismutase (antioxidant defence), cytochrome c oxidase (mitochondrial energy production), lysyl oxidase (collagen and elastin crosslinking) and ceruloplasmin (iron metabolism).

GHK acts as a carrier peptide for copper, facilitating its uptake into cells in a bioavailable form. The tripeptide sequence has a high affinity for Cu(II) ions, forming a stable chelate complex. Research has proposed that this copper delivery function is one of the primary mechanisms through which GHK-CU exerts its studied biological effects — particularly in the context of enzymes that require copper as a cofactor.

The molecular weight of GHK-CU is approximately 340.4 Da for the peptide component, with the copper complex adding approximately 63.5 Da. This small molecular size is relevant to its behaviour in laboratory models, particularly regarding cellular uptake studies.

Key Research Areas

Collagen Synthesis Research

Perhaps the most extensively studied area of GHK-CU research involves its effects on collagen production. Laboratory studies have demonstrated that GHK-CU can upregulate collagen synthesis in fibroblast cultures, with observed effects on both collagen type I and type III expression. Research has also examined its effects on matrix metalloproteinase (MMP) regulation — particularly the balance between collagen-degrading enzymes and their inhibitors (TIMPs) — suggesting a role in collagen remodelling as well as production.

Skin Biology and Wound Healing Research

GHK-CU has been studied in multiple skin biology contexts. In wound healing models, research has examined effects on keratinocyte migration, fibroblast proliferation, angiogenesis (via VEGF-related pathways) and dermal matrix organisation. The peptide has been studied both in cell culture models and in vivo wound models, with interest in its ability to influence the rate and quality of skin repair processes.

Studies have also examined GHK-CU's antioxidant properties in skin cell models, with research identifying interactions with NF-κB signalling (a key inflammatory mediator) and SOD1/SOD2 (superoxide dismutase) expression in dermal cells.

Hair Follicle Research

Hair follicle biology represents a growing area of GHK-CU research interest. Studies have examined the peptide's effects on human hair follicle cell cultures, investigating keratinocyte proliferation, follicle size in ex vivo models and the expression of growth factors relevant to follicle biology including KGF (keratinocyte growth factor) and IGF-1. The copper-dependent enzyme lysyl oxidase has particular relevance to hair structure research given its role in keratin crosslinking.

Gene Expression Research

A distinctive area of GHK-CU research involves its broad effects on gene expression. Studies using microarray analysis have identified GHK-CU as a modulator of gene expression across a wide range of biological systems, with one analysis identifying over 4,000 genes with altered expression profiles in response to GHK-CU. This broad transcriptional activity has been interpreted by some researchers as evidence of a fundamental regulatory role, though the full implications remain an active area of investigation.

Anti-Ageing and Cellular Biology Research

The age-dependent decline of GHK-CU in plasma has motivated research into its potential roles in cellular ageing processes. Studies have examined GHK-CU in the context of proteasome activity (the cellular protein degradation system), mitochondrial function, DNA repair mechanisms and the biology of cellular senescence. These represent broader systemic research interests extending beyond the skin-focused applications more commonly discussed.

GHK-CU in Peptide Blends

GHK-CU forms the primary component (50mg) of both GLOW70 and KLOW80 — the premium research blends available from 121 Peptides. Its combination with BPC 157 (tissue repair, NO system) and TB500 (actin dynamics, cell migration) creates a multi-mechanism research formulation targeting complementary pathways in skin biology, wound healing and cellular regeneration.

Frequently Asked Questions About GHK-CU

Related Research Articles

Enquire About GHK-CU Research Supply

121 Peptides supplies GHK-CU in 50mg and 100mg formats for laboratory research. Submit a research enquiry.